249 results on '"Carlyle, Becky C."'
Search Results
2. Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer’s disease in a large clinical sample
3. Transcriptome and epigenome landscape of human cortical development modeled in organoids
4. Integrative functional genomic analysis of human brain development and neuropsychiatric risks
5. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease
6. Interrogation of the human cortical peptidome uncovers cell-type specific signatures of cognitive resilience against Alzheimer’s disease
7. Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer’s disease
8. Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease
9. Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics
10. High VEGF‐A and low PlGF in plasma are associated with reduced longitudinal tau PET burden and slower cognitive decline in preclinical Alzheimer’s disease
11. iPSC‐derived cortical neurons of sporadic Alzheimer’s disease patients reflect their clinical vulnerability
12. Investigating Selective Neuronal Vulnerability in Alzheimer’s and Parkinson’s Disease with Induced Pluripotent Stem Cells and Pre‐formed Fibrils
13. Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort
14. The Role of Inflammation after Surgery for Elders (RISE) study: Study design, procedures, and cohort profile
15. Correction to “Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer’s Disease”
16. The aged rhesus macaque manifests Braak stage III/IV Alzheimer's-like pathology
17. A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment
18. Mass Spectrometry in Cerebrospinal Fluid Uncovers Association of Glycolysis Biomarkers with Alzheimer’s Disease in a Large Clinical Sample
19. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease
20. Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer’s Disease
21. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment
22. A multiregional proteomic survey of the postnatal human brain
23. Using Proteomics Analysis to Identify Cerebrospinal Fluid Biomarkers in Normal Pressure Hydrocephalus
24. Evaluating the biological variability of blood‐based biomarkers for use in clinical trials
25. Applying Data‐Independent Acquisition Mass Spectrometry on Cerebrospinal Fluid Samples from a Neurology Clinic for Biomarker Discovery in Alzheimer’s Disease
26. cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex
27. Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment
28. Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's Disease
29. Proteomic characterization of post-mortem human brain tissue following ultracentrifugation-based subcellular fractionation
30. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment
31. Additional file 1 of Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease
32. Additional file 2 of Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease
33. Increased levels of the synaptic proteins PSD-95, SNAP-25, and Neurogranin in the cerebrospinal fluid of patients with Alzheimer’s Disease
34. Characterizing proteoforms of the granin family of neuropeptides in dementia pathophysiology
35. Using cerebrospinal fluid ATN quantification to classify research subjects in a diverse clinical population
36. Characterization of novel neuropeptide proteolytic processing involved in dementia pathophysiology
37. Levels of the synaptic proteins PSD‐95, SNAP‐25, and neurogranin are selectively increased in the cerebrospinal fluid of patients with Alzheimer’s disease
38. Altered brain functional connectivity and cardiovascular and metabolic risk factors in middle‐aged and older adults
39. Technical performance and biotemporal stability evaluation of Olink proximity extension assay for blood‐based biomarker discovery
40. The technical reliability and stability of ATN quantification using the Fujirebio Lumipulse G1200 fully‐automated immunoassay instrument in cerebrospinal fluid
41. A comparison of multiple platforms for quantifying ATN values in cerebrospinal fluid
42. Matrix metalloproteinase‐10 as a novel biomarker of neurodegeneration in Alzheimer’s disease
43. Roadblock: improved annotations do not necessarily translate into new functional insights
44. VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases
45. Plasma biomarkers for prognosis of cognitive decline in patientswithmild cognitive impairment.
46. Correction to: Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
47. Additional file 1 of Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
48. Plasma IL‐12/IFN‐γ axis predicts cognitive trajectories in cognitively unimpaired older adults
49. Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
50. Neuroanatomical changes in a mouse model of early life neglect
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.